Evonik Adjusts Revenue Outlook Amid Strategic Price Hike

Evonik lowers 2026 sales outlook but holds earnings target, announces 10% price increase for MetAMINO® to counter weak volumes and Q4 2025 revenue decline.

The Essen-based specialty chemicals group Evonik has revised its 2026 revenue forecast downward, though it reaffirmed its earnings targets. This move signals persistent challenges in certain business segments. Concurrently, the company is implementing a classic strategic lever: a substantial price increase for a core product.

Annual Results Reflect Fourth-Quarter Weakness

Evonik's full-year revenue for 2025 totaled €14.1 billion, representing a 7 percent decline. The company's full-year adjusted EBITDA came in at €1.87 billion. A weak final quarter significantly impacted the annual figures, with fourth-quarter sales dropping 5 percent to €3.40 billion. Adjusted EBITDA for Q4 2025 fell 8 percent to €357 million. However, the bottom line showed improvement: the quarter ended with a net profit of €18 million, a notable recovery from a net loss of €152 million in the same period a year earlier.

The company's board has proposed a dividend of €1.00 per share for the 2025 financial year. Shareholders will vote on this proposal at the Annual General Meeting scheduled for June 3.

Price Increase for MetAMINO® Announced

In a parallel development, Evonik's Animal Nutrition division announced a significant price adjustment. Effective March 5, the price for its product MetAMINO® will increase by a net 10 percent across all markets. This measure is aimed at stabilizing margins in an operating environment where volume growth has become more challenging to achieve.

Revised Guidance: Earnings Target Holds, Revenue Forecast Trimmed

For the current fiscal year, Evonik maintains its guidance for adjusted EBITDA, which is projected to be between €1.7 billion and €2.0 billion. The revenue outlook, however, has been narrowed. Management now expects sales in the range of €13.5 billion to €14.5 billion, a reduction from a previously higher midpoint expectation. This adjustment underscores the ongoing headwinds facing parts of the business.

Investors are now assessing whether the combined strategy of strategic pricing and ongoing cost discipline will be sufficient for the company to meet its earnings objectives. Evonik's share price has faced considerable pressure, declining nearly 36 percent over the past twelve months.